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Artemisia herba-alba	(A. h.-a.)	has	wide	use	in	traditional	medicine	for	the	relief	of	cough-
ing,	healing	external	wounds,	and	 treatment	of	pain	associated	with	gastrointestinal	distur-
bances.	We	investigated	in vivo antinociceptive	and	anti-inflammatory	activities	of	an	aque-
ous	extract	(aq.	ex.)	and	two	isolated	compounds	obtained	from	aerial	parts	of	A. h.-a.	The	
analgesic	effects	of	aq.	ex.	 (10,	31.6,	100,	316,	and	1000	mg/kg),	 astragalin,	and	eupatilin	
(both,	0.316,	1,	3.16,	10,	31.6,	and	100	mg/kg)	were	studied	using	the	hot-plate	test	in	mice	
and	formalin	test	in	rats.	The	effects	were	compared	with	those	of	5	mg/kg	morphine.	Dose-
dependent	 analgesic	 effects	of	 aq.	 ex.,	 astragalin,	 and	 eupatilin	were	 clearly	manifested	 in	
both	hot-plate	assay	and	early	and	late	phases	of	formalin-induced	paw	licking.	These	effects	
were	significantly	but	partly	reduced	by	the	opioid	receptor	antagonist	naloxone	(5	mg/kg).	
The	same	range	of	doses	of	aq.	ex.,	astragalin,	and	eupatilin	caused	dose-dependent	suppres-
sion	of	carrageenan-induced	paw	edema	in	rats.	Thus,	we	demonstrated	that	A. h.-a. possesses 
noticeable	antinociceptive	and	anti-inflammatory	activities;	our	data	support	the	reasons	for	
using	 this	 plant	 as	 a	 remedy	 for	 treatment	 of	 pain	 and	 inflammation.	Antinociceptive	 and	
anti-inflammatory	actions	of	A. h.-a.	 are	 considerably	 related	 to	 the	presence	of	 astragalin	
and	eupatilin.
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INTRODUCTION
Artemisia herba-alba	 (A. h.-a.)	 is	 a	 subspecies	 of	
Artemisia alba (family	 Asteriacea);	 sometimes	 it	 is	
qualified	as	a	separate	species.	It	is	a	strongly	aromatic	
herb,	 with	many	 erect	 and	 leafy	 stems	 (20-40	 cm	 in	
height)	 and	 leafs	 covered	 by	woolly	 hairs.	Artemisia 
herba-alba	 grows	widely	 in	 Jordan	 and	 in	 the	 entire	
Middle	 East,	 as	 well	 as	 in	 some	 other	 regions	 of	
Europe	 and	Asia.	 In	 Jordan,	 this	 plant	 is	 common	 in	
dry	mountains	and	desert	regions	[1].
Artemisia herba-alba	 has	 wide	 use	 (mainly	 as	
anthelmintic	 and	 antispasmodic)	 in	 traditional	
medicine.	 It	 is	 also	 used	 as	 a	 remedy	 for	 coughing,	
external	wounds,	falling	hair,	gastric	disturbances,	and	
jaundice	 [2-6].	 It	was	also	 reported	 that	a	 tincture	of	
the leaves of this species can be used as an antidiabetic 
(hypoglycemic)	 and	 sedative	 drug	 [7].	 Moreover,	
there was reported that agents from this plant manifest 
antifungal,	 antibacterial,	 leishmanicidal,	 antipyretic,	
antiallelopathic,	 and	 antioxidant	 activities	 [8,	 9].	
Recently,	 the	 neurological	 activities	 of	 an	 ethanolic	
extract	and	some	flavonoids	 from	A. h.-a.	have	been	
demonstrated	[10].	An	aqueous	extract	(aq.	ex.)	of	A. 
h.-a.	was	 found	 to	 inhibit	hemolytic	activities	of	 the	
viper	and	scorpion	venoms	[11].	
Phytochemical	 studies	 of	 A. h.-a.  revealed 
the	 presence	 of	 santonin,	 sequiterpene	 lactones,	
camphor,	 1,8-cineole,	 p-cymene,	 davanone,	 cineol-
thujanebornane,	 pinane,	 α-	 and	 β-thujones, 	 a	
chrysanthenyl	 derivative,	 quercetin-3’-glucoside,	
quercetin-3-O-rutinoside,	 5,4’-dihydroxy-6,7,3’-
trimethoxyflavone,	 dinatin	 (4’,5,7-trihydroxy-6-
methoxyflavone),	 skrofulein	 (4’,7-dihydroxy-6,7’- 
dimethoxyflavone),	 essential	 oils,	 and	 eudesmano- 
lides	 [2,	 6,	 12-15].	 Components	 of	 the	 essential	 oil	
from	A. h.-a.	have	also	been	investigated	[16-19].
Despite	 the	 traditional	 use	 of	 A. h.-a.  as an 
analgesic, 	 no	 systemic	 studies	 concerning	 its	
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antinociceptive effects have been carried out to 
affirm the traditional use and to establish chemical 
principles	responsible	for	the	activities	reported.	Here,	
we describe for the first time the antinociceptive and 
anti-inflammatory	 effects	of	 an	 aqueous	 extract	 (aq.	
ex.)	of	A. h.-a. aerial parts and two known flavonoids 
(astragalin	and	eupatilin)	 isolated	 from	 this	plant.	 In	
addition,	our	results	showed	that	these	two	flavonoids	
are the major compounds of this plant responsible for 
its	antinociceptive	effects.
METHODS
Plant Material. Aerial parts of wild-growing 
A. h.-a. were collected during April from Al-Mafraq 
(Jordan)	 by	 one	 of	 the	 authors.	 The	 plant	 material	
was	identified	and	authenticated	taxonomically	at	the	
Hashemite	University	herbarium.	A	voucher	specimen	
was	 deposited	 under	 the	 number	 HU-255	 at	 the	
Hashemite	 University	 herbarium,	 Zarka,	 Jordan,	 for	
future	reference.
Preparation of the aq.  ex. The	 extract	 was	
obtained	 by	 boiling	 150	 g	 of	 air-dried	 aerial	 parts	
of	A. h.-a.	 in	 1000	ml	 of	 distilled	water	 for	 60	min	
with	 continuous	 stirring.	The	 resultant	 solution	was	
filtered	 through	Whatman	 filter	 paper.	 The	 filtrate	
was	 completely	 evaporated	 under	 reduced	 pressure	
at	50°C	 to	give	10	g	of	a	gummy	material.	Solutions	
were	prepared	by	dissolving	weighed	amounts	of	this	
material	in	physiological	salt	solution	(PSS).	The	latter	
had	the	following	composition	(mM):	NaCl,	118;	KCl,	
4.7;	NaHCO
3
,	25;	NaH
2
PO
4
	 ∙	H
2
O,	1;	Na
2
HPO
4
,	0.5;	
glucose,	11.1;	MgCl
2
	 ∙	6H
2
O,	0.5,	and	CaCl
2
	 ∙	2H
2
O,	
2.5;	pH	of	the	stock	solution	was	adjusted	to	7.4.
Extraction and Fractionation Procedures. Air-
dried and powdered aerial parts of A. h.-a.	 (3500	g)	 
were	 extracted	 by	 successive	 macerations	 with 
dichloromethane	and	50%	aqueous	ethanol.	Extracts	
were filtered and concentrated in vacuum to obtain 
dry	dichloromethane	(5.3%)	and	50%	ethanol	extracts	
(16.2%).	The	dichloromethane	 extract	was	 adsorbed	
on	 Celite	 and	 eluted	 successively	 with	 hexane,	
toluene,	 diethyl	 ether,	 and	 acetone,	 with	 a	 final	
wash	 with	 methanol.	 Four	 main	 fractions,	 F1–F4,	
were	obtained	 and	dried	under	vacuum.	The	F3	was	
separated	on	a	Silicagel	60	column	(Merck,	Germany)	
eluted	with	gradients	of	cyclohexane–ethyl	acetate	and	
ethyl	acetate–acetone	 to	yield	11	fractions.	Fractions	
3.V	 and	3.VI	were	 combined	 (F	3.V–VI),	 submitted	
to	 gel	 permeation	 on	 a	 Sephadex	 LH-20	 column	
(Pharmacia,	USA),	and	eluted	with	methanol	to	afford	
36	 subfractions.	 Subsequent	 differentiation	 of	 the	
constituents of these fractions using chromatographic 
techniques	 allowed	 us	 to	 obtain	 the	 necessary	
amounts	of	compounds	1	and	2.	The	structure	of	these	
compounds corresponded to those of astragalin and 
eupatilin	 (5,7-dihydroxy-6,3’,4’-trimethoxyflavone),	
respectively	 (Fig.	 1),	 through	 comparison	 of	 their	 
1H	NMR,	MS,	and	IR	with	those	previously	reported	
in	literature	[20,	21].	Other	extracts	and	fractions	were	
not	 investigated	 in	 our	 study	 since	 their	 biological	
activity	was	low.
Experimental Procedures. Non-fasting	 male	
Wistar	rats	(150-250	g)	and	mice	(22-30	g),	housed	at	
22-25	°C	under	a	12	h	light/dark	cycle	and	with	access	
to food and water ad libitum,	were	used	throughout	the	
experiments.	
Hot-Plate Test was assessed using groups of male 
mice,	six	animals	per	group.	The	hotplate	 temperature	
was	maintained	at	50	±	1°C.	The	latency	of	a	discomfort	
reaction,	 licking	paws	(sec),	was	measured	before	and	 
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F i g. 1.	Chemical	structure	of	
astragalin	 (A)	 and	 eupatilin	
(B).
Р и с. 1. Хімічна	структура	
астрагаліну	 (А)	 та	
еупатиліну	(В).
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60	 min	 after	 i.p.	 administrations	 of	 10	 ml/kg	 PSS	
(control),	 A. h.-a.	 aq.	 ex.	 (10,	 31.6,	 100,	 316,	 and	 
1000	mg/kg),	astragalin,	eupatilin	(both,	0.316,	1,	3.16,	
10,	31.6,	and	100	mg/kg),	or	morphine	(5	mg/kg;	positive	
control).	 The	 largest	 doses	 were	 determined	 on	 the	
basis	of	LD50	experiments	(for	aq.	ex.)	or	values	of	the	
practical	solubility	(for	astragalin	and	eupatilin).	Smaller	
doses	were	calculated	as	corresponding	to	approximately	
0.5	log	units	from	each	other	on	the	log	scale.	The	cut-
off	 time	 was	 60	 sec.	Means	 of	 three	 readings	 of	 the	
reaction	time	obtained	before	administration	of	PSS,	aq.	
ex.,	astragalin,	eupatilin,	or	morphine	were	considered	
baselines as normal reaction times of animals to the 
temperature	 used.	 Increases	 over	 baseline	 (%)	 were	
calculated according to the mean of three readings of 
the	latency	after	treatment	measured	within	5-7	min;	the	
latencies	 before	 treatment	were	 taken	 as	 100%.	 In	 all	
experiments,	ED50	values	were	determined	from	the	plot	
of	individual	experiments	by	the	best	visual	fit. 
Formalin Test.	Rats	were	divided	 into	groups	(six	
rats	each)	and	 injected	 i.p.	with	either	PSS	(control),	
aq.	ex.	of	A. h.-a.,	astragalin,	or	eupatilin	in	the	doses	
mentioned	 above,	 or	 5	 mg/kg	 morphine	 (positive	
control).	Sixty	min	 later,	50	μl	of	 formalin	 (5%)	was	
injected into the dorsal surface of the right hind paw of 
each	rat	using	a	microsyringe	[22].	Immediately	after	
formalin	injection,	animals	were	placed	individually	in	
acrylic	observation	chambers	(320	cm2	×	40	cm);	clear	
observation of the paws of the animals was provided 
by	mirrors.	Licking	of	the	injected	paw	was	defined	as	
the	nociceptive	 response.	Total	 times	of	 the	 response	
were	measured	during	 the	periods	 of	 0-5	min	 (early	
phase)	and	15-40	min	(late	phase);	normalized	values	
of	inhibition	of	licking	(%)	were	calculated.	
Carrageenan-Induced Edema in Rats [23].	Groups	
of	 five	 animals	 each	 were	 used.	 Paw	 swelling	 was	
elicited	with	 0.1	ml	 1%	 carrageenan	 in	 0.9%	 saline	
(w/v)	injected	into	the	right	hind	foot	under	the	plantar	
aponeurosis.	Test	groups	of	 the	 rats	were	 treated	 i.p.	
1	h	before	 carrageenan	 injection	with	10	ml/kg	PSS	
(control),	aq.	ex.,	astragalin,	and	eupatilin	(in	the	doses	
mentioned	above),	or	10	mg/kg	indomethacin	(positive	
control).	The	inflammation	intensity	was	quantified	by	
measuring	 the	volume	displaced	by	 the	paw,	using	a	
plethysmometer	(Ugo	Basile,	Italy)	at	time	points	0,	1,	
2,	3,	and	5	h	after	carrageenan	 injection.	Normalized	
intensities	of	inflammation	(%)	were	calculated.
Involvement of the Opioid System in the 
Antinociceptive Action of A. h.-a. To evaluate the 
mechanism	of	action	of	aq.	ex.,	astragalin,	or	eupatilin,	
animals	were	pre-treated	i.p.	with	the	opioid antagonist 
naloxone	(5	mg/kg)	15	min	before	administrations	of	
PSS	or	ED50s	of	 the	extract,	astragalin,	eupatilin,	or	
5	mg/kg	morphine.	Using	 the	hot-plate	and	 formalin	
tests	 as	 described	 above,	we	measured	 the	 latencies	
of	nociceptive	reactions	60	min	after	administration.
Statistical  Analysis.  Numerical 	 values	 are	
expressed	below	as	means	±	s.e.m.	Data	were	treated	
by	one-way	analysis	of	variance	 (ANOVA)	 followed	
by	 the	 Duncan’s	 test	 for	 multiple	 comparisons.	
Differences were considered significant when P	<0.05.
RESULTS
Antinociceptive Effects of A. h.-a. Aq. Ex., 
Astragalin, and Eupatilin. 
Hot-Plate Assay. Treatment	of	animals	with	the	aq.	
ex.	of A. h.-a.	 (10,	31.6,	100,	316,	and	1000	mg/kg,	 
i.p.,	60	min	prior),	astragalin,	(0.316,	1,	3.16,	10,	31.6,	
and	 100	mg/kg,	 i.p.,	 60	min	 prior),	 or	 eupatilin	 (in	
the	 same	 doses	 and	mode)	 caused	 significant	 dose-
dependent	(P < 0.05)	increases	in	the	response	latency	
in	the	hot-plate	test	with	ED50s	of	56.2	±	3.7,	5.61	±	 
±	0.41,	and	3.92	±	0.32	mg/kg,	 respectively	 (Fig.	2).	
The same	 doses	 of	 aq.	 ex.,	 astragalin,	 and	 eupatilin	
given	 i.p.	 did	 not significantly	 affect	 the	 motor	
performance of the animals (control	 response	 in	 the	
rota-rod	 test	was	 120	±	 2.1	 sec	vs 120	±	 1.1,	 119	±	 
±	2.2,	and	122	±	1.6	sec	in	the	presence	of	the	greatest	
doses	of	aq.	ex.,	astragalin,	and	eupatilin,	respectively;	 
n	=	6).
Formalin Test. Intraplantar	injections	of	5%	formalin	
evoked characteristic biphasic licking responses in the 
rats.	As	is	shown	in	Fig.	3,	pre-treatment	(60	min)	with	
different doses of A. h.-a. aq.	ex.,	astragalin,	and	eupatilin	
(in	the	doses	mentioned	above)	caused	significant	dose-
related suppression of both phases of formalin-induced 
pain	in	rats.	For	the	early	phase,	the	ED50	values	for	the	
aq.	ex.,	astragalin,	and	eupatilin	were	44.5	±	3.4,	5.6	±	 
±	0.31,	and	2.26	±	0.12	mg/kg,	while	the	ED50	values	for	
the	late	phase	were	31.6	±	3.1,	3.16	±	0.34,	and	1.78	±	 
±	0.2	mg/kg	for	these	agents,	respectively.
Effects of Naloxone. The	results	shown	in	Table	1	 
indicate that the antinociceptive effect of morphine 
(5	mg/kg,	 s.c)	was	 fully	 reversed	by	prior	 treatment	
of	 the	 animals	 with	 naloxone	 (5	 mg/kg,	 i.p.).	 This	
was related to both phases of formalin-induced 
pain	 and	 the	 response	 latency	 in	 the	 hot-plate	 test	 
(P <	 0.001).	At	 the	 same	 time,	 pretreatment	 of	 the	
animals	 with	 naloxone	 in	 the	 same	 dose	 noticeably	
but	 only	 partly	 reversed	 antinociceptive	 effects	 of	 
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F i g. 2.	 Effects	 of	 the	 aqueous	 extract	 from	 Artemisia herba-
alba	 (A),	 astragalin	 (B),	 and	 eupatilin	 (C)	on	 the	 latency	of	 limb	
withdrawal	 in	 mice	 submitted	 to	 the	 hotplate	 test.	 Values	 were	
expressed	as	means	±	s.e.m	(n =	6).	Horizontal	scale)	Doses	of	the	
agents	used,	mg/kg;	contr.	is	the	control,	and	morph.	is	morphine,	
5	mg/kg.	Vertical	scale)	Normalized	increments	with	respect	to	the	
baseline	values	taken	as	100%.
Р и с. 2. Впливи	водного	екстракту	білого	полину	(А),	астрагаліну	
(В)	 та	 еупатиліну	 (С)	 на	 латентні	 періоди	 ноцицептивних	
реакцій	у	мишей	в	тесті	„гарячої	платівки”.
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F i g. 3.	 Effects	 of	 the	 aqueous	 extract	 from	
Artemisia herba-alba	 (A),	 astragalin	 (B),	 and	
eupatilin	(C)	on	the	intensities	of	the	pain	reaction	
(licking	the	limb)	within	early	(0-5	min)	and	late	
(15-40	min)	 phases	 of	 the	 formalin	 test	 in	 rats.	
Vertical	 scale)	 Normalized	 values	 of	 inhibition,	
%;	the	baseline	intensities	are	taken	as	100%.	
Р и с. 3. Впливи	 водного	 екстракту	 білого	
полину	(А),	астрагаліну	(В)	та	еупатиліну	(С)	
на	 інтенсивність	 больових	 реакцій	 (лизання	
кінцівки)	в	перебігу	ранньої	(0–5	хв)	та	пізньої	
(15–40	хв)	фаз	формалінового	тесту	у	щурів.
mg/kg mg/kg
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Table 4. Effects of eupatilin against carrageenan-induced paw edema in rats. Values are expressed as means ± s.e.m. (n = 6). * 
Significant differences from the control (P < 0.05).
Т а б л и ц я 4. Ефекти еупатиліну щодо індукованого карагенаном набряку кінцівки у щурів
Treatment Dose,	mg/kg Time	after	carrageenan	injections,	h
1 2 3 5
Control 22.6	±	1.3 32.2	±	3.1 51.2	±	1.9 47.1	±	3.5
Eupatilin 0.316 22.3	±	0.9 29.6	±	1.2* 35.6	±	1.5* 33.4	±	3.2*
Eupatilin 1 19.7	±	1.2* 26.1	±	1.1* 26.1	±	2.4* 23.2	±	1.5*
Eupatilin 3.16 21.3	±	1.9* 24.3	±	1.9* 22.5	±	1.3* 21.5	±	2.3*
Eupatilin 10 17.2	±	1.1* 15.1	±	1.4* 14.3	±	0.4* 13.2	±	0.9*
Eupatilin 31.6 15.1	±	2.1* 12.2	±	1.3* 11.2	±	0.9* 11.1	±	1.1*
Eupatilin 100 13.3	±	1.4* 10.5	±	1.3* 10.3	±	0.4* 10.1	±	0.8*
Indomethacin 10 11.2	±	1.2* 10.1	±	1.1* 10.5	±	1.4* 11.3	±	1.3*
Footnotes.	In	Tables	2	–	4,	values	are	expressed	as	means	±	s.e.m.	(n	=	6).	*	Significant	differences	from	the	control	(P	<	0.05)
Table 1. Effects of naloxone on the Artemisia herba-alba aqueous extract-, astragalin-, and eupatilin-induced antinociceptive activity 
Т а б л и ц я 1. Впливи налоксону на антиноцицептивну активність, індуковану екстрактом білого полину, астрагаліном та 
еупатиліном
Treatment Hotplate
increase	in	baseline	(%)
Inhibition	(%)	of	licking	 
phase I
Inhibition	(%)	of	licking	
phase II
Control 2	±	0.30 1.7	±	0.14 3.1	±	0.41
Artemisia herba-alba	aq.	ex.	(ED50) 50 50 50
Astragalin(ED50) 50 50 50
Eupatilin(ED50) 50 50 50
Morphine 80	±	3.70 75	±	4.10 85	±	4.52
Naloxone 3.0	±	0.23 2.7	±	0.15 1.3	±	0.10
Morphine+Naloxone 4.1	±	0.71 5.4	±	1.20 5.3	±	0.40
Artemisia herba alba	aq.	ex.	+Naloxone 10	±	1.10* 15	±	2.32* 25	±	3.61*
Astragalin+Naloxone 14	±	2.10* 25	±	3.41* 22	±	1.93*
Eupatilin+Naloxone 18	±	2.70* 30	±	5.12* 18	±	2.70*
Footnotes.	Values	are	expressed	as	means	±	s.e.m.	(n	=	6).	*Significant	differences	from	the	effects	provided	by	the	aqueous	extract,	
astragalin,	and	eupatilin.	The	doses	of	Artemisia herba-alba	aqueous	extract,	astragalin,	and	eupatilin	used	corresponded	to	the	ED50.
Table 2. Effects of the Artemisia-herba alba aqueous extract on carrageenan-induced paw edema in rats 
Т а б л и ц я 2.  Ефекти водного екстракту білого полину щодо індукованого карагенаном набряку кінцівки у щурів
Treatment Dose,	mg/kg Time	after	carrageenan	injections,	h
1 2 3 5
Control 22.3	±	2.7 34.1	±	1.4 50.1	±	2.7 45.2	±	2.4
Extract 10 21.5	±	1.6 30.4	±	1.2* 33.7	±	1.4* 32.7	±	1.7*
Extract 31.6 20.2	±	1.1 27.2	±	1.1* 28.3	±	2.1* 27.1	±	1.3*
Extract 100 22.1	±	0.9 25.7	±	1.9* 23.7	±	1.5* 23.3	±	2.1*
Extract 316 16.4	±	1.3* 18.8	±	1.7* 16.3	±	0.5* 15.1	±	1.4*
Extract 1000 14.3	±	1.2* 11.1	±	1.6* 10.5	±	0.7* 13.1	±	0.7*
Indomethacin 10 10.7	±	1.5* 9.9	±	1.3* 10.3	±	1.2* 11.7	±	2.5*
Table 3. Effects of astragalin against carrageenan-induced paw edema in rats
Т а б л и ц я 3. Ефекти астрагаліну щодо індукованого карагенаном набряку кінцівки у щурів
Treatment Dose,	mg/kg Time	after	carrageenan	injections,	h1 2 3 5
Control 21.3	±	1.7 30.5	±	1.9 52.3	±	1.6 49.8	±	3.1
Astragalin 0.316 20.1	±	1.2 27.3	±	1.7* 38.3	±	2.1* 36.3	±	2.5*
Astragalin 1 22.5	±	0.9 25.7	±	1.4* 23.8	±	1.7* 24.2	±	1.1*
Astragalin 3.16 21.7	±	1.6 24.3	±	1.7* 20.6	±	2.1* 22.1	±	3.1*
Astragalin 10 17.5	±	0.9* 17.3	±	2.3* 14.2	±	1.5* 13.2	±	1.1*
Astragalin 31.6 15.6	±	1.3* 11.5	±	1.8* 11.1	±	1.7* 11.7	±	1.2*
Astragalin 100 13.1	±	1.1* 10.6	±	1.1* 11.3	±	0.7* 10.2	±	0.9*
Indomethacin 10 10.4	±	1.2* 10.1	±	1.2* 9.8	±	0.9* 11.3	±	1.5*
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A. h.-a. aq.	ex.,	astragalin,	and	eupatilin.	The	effects	
were more pronounced in the formalin test than in the 
hot-plate	 test.	Naloxone	exerted	 insignificant	effects	
on	the	control	animals	that	received	PSS.	The	aq.	ex.,	
astragalin,	and	eupatilin	doses	used	were	nearly	equal	
to	those	corresponding	to	the	ED50s.	
Anti-Inflammatory Effects of Aq. Ex. of A. h.-a., 
Astragalin, and Eupatilin. Preliminary	experiments	
showed that the degree of swelling of the carrageenan-
injected	rat	paws	was	maximal	at	3	h	after	injection	of	
carrageenan.	Tables	2,	3,	and	4	show	the	effects	of	A.	
aq.	ex.,	astragalin,	eupatilin,	and	indomethacin	in	the	
carrageenan-induced	 edema	 test.	 Statistical	 analysis	
proved	that	inhibition	of	edema	exerted	by	aq.	ex.	and	
its	 compounds	was	 dose-dependent,	 and	 significant	
differences	 from	 the	 control	 group	 were	 observed.	
The results showed that astragalin and eupatilin in 
doses	 of	 100	 mg/kg	 provided	 anti-inflammatory	
effects	 comparable	 to	 those	 produced	 by	 10	 mg/kg	
indomethacin.
DISCUSSION
Our	 study	 demonstrated	 that	 i.p.	 administrations	 of	
the	 aq.	 ex.,	 astragalin,	 and	 eupatilin	 obtained	 from	
A. h.-a. exerted	 both	 clear	 antinociceptive	 and	 anti-
inflammatory	 effects	 in	 mice	 and	 rats.	 In	 the	 hot-
plate	test,	i.p.	treatment	by	the	aq.	ex.,	astragalin,	and	
eupatilin provided antinociceptive effects in a dose-
dependent	 manner.	 Increases	 in	 the	 reaction	 latency	
showing nociception effects in animals treated with 
the	 above	 agents	 in	 nearly	 all	 doses	were	 significant	
when	 compared	 to	 control	 animals	 treated	with	 PSS.	
The	 same	 delay	 in	 the	 reaction	 time	 was	 obvious	
when morphine was used in a dose known to have 
a	 potent	 analgesic	 effect	 [24].	 The	 efficacies	 of	 aq.	
ex.,	 astragalin,	 or	 eupatilin,	 however,	 were	 much	
lower than that of morphine even when the greatest 
doses	were	 used	 (1000,	 100,	 and	 100	mg	 for	 the	 aq.	
ex.,	astragalin,	and	eupatilin,	respectively).	The	paw-
licking	hot-plate	response	 is	a	complex	supraspinally	
organized	 behavioral	 phenomenon	 [25].	The	 efficacy	
of A. h.-a. aq.	ex.	in	the	hot-plate	test	might	be	due	to	
analgesic	 agent(s)	 (such	 as	 astragalin	 and	 eupatilin)	
acting	primarily	at	the	spinal,	medullary,	and/or	higher	
levels	 of	 the	 CNS	 or	 by	 some	 indirect	 mechanisms	
[26-28].	
The	 results	of	our	study	also	demonstrated	 that	A. 
h.-a. aq.	 ex.-,	 astragalin-,	 or	 eupatilin-treated	 rats	
showed	decreased	nociceptive	behaviors	 induced	by	
intraplantar formalin administration during both initial 
and	late	phases	of	the	test	in	a	dose-dependent	manner.	
The first acute phase of the nociceptive response in the 
rat	 formalin	 test	 lasts	 for	about	5	min	after	 formalin	
injection,	and	it	is	followed	by	the	second	tonic	phase,	
which	persists	 from	30	 to	60	min	after	 injection	 [26-
29].	 It	 is	widely	accepted	 that	 the	 first	phase	 results	
from a direct effect on nociceptors activating thin 
primary	 afferent	 fibers	 (C-fibers),	while	 the	 second	
phase	 represents	 a	 tonic	 inflammatory	 nociceptive	
phenomenon	[28,	30-31].	
The observation that antinociceptive activities of A. 
aq.	ex.,	astragalin,	and	eupatilin	were	 reduced	partly	
by	pretreatment	with	naloxone,	an	antagonist	of	opioid	
receptors,	 suggests	 that	 the	 action	 of	 the	 extract, 
astragalin,	and	eupatilin	may	be	mediated	not	only	by	
the	 action	 on	 the	 above	 receptors	 but	 also	 by	 some	
other	 mechanisms.	 Recent	 studies	 have	 shown	 that	
formalin	 activates	 primary	 afferent	 sensory	 neurons	
(C-fibers)	through	a	specific	direct	action	on	TRPA1s,	
members	 of	 the	Transient	Receptor	Potential	 family	
(TRP)	 possessing	 cation	 channels,	which	 are	 highly	
expressed	in	a	subset	of	C-fiber	nociceptors	[32].	This	
effect	is	accompanied	by	increased	influx	of	Ca2+	ions.	
To	investigate	the	involvement	of	TRPA1	receptors	in	
the antinociceptive effect of A. h.-a.	aq.	ex.,	astragalin,	
and	eupatilin,	we	assessed	the	cinnamaldehyde-induced	
nociception	 test.	Currently,	 it	has	been	demonstrated	
that	 intraplantar	administration	of	cinnamaldehyde,	a	
TRPA1	 receptor	 agonist,	 produces	 a	dose-dependent	
spontaneous	 nociception	 effect	 in	 mice	 [33].	 Our	
results showed that A. h.- a. aq.	 ex.,	 astragalin,	 and	
eupatilin	 significantly	 suppressed	 cinnamaldehyde-
induced	pain	 (unpublished	observations).	This	 result	
indicates that A.	 aq.	 ex.	 constituents	 (astragalin	 and	
eupatilin)	probably	interact	with	TRPA1	receptors	with	
C-fibers	and	reduce	the	formalin-induced	nociception.	
It has also been proposed that the capsaicin-induced 
nociception	is	brought	about	by	activation	of	another	
type	of	TRP	receptors,	the	vanilloid	receptors	(TRPVs)	
termed	TRPV1;	 these	are	 ligand-gated	non-selective	
cation	channels	 in	primary	 sensory	neurons	 [34-36].	
Our	results	also	showed	that	administration	of	A. h.-a. 
aq.	ex.,	astragalin,	and	eupatilin	produced	partial	(but	
significant)	 reduction	 of	 the	 nociceptive	 responses	
caused	by	intraplantar	injections	of	capsaicin	into	the	
mouse	hindpaw	(unpublished	observations).	
It	was	 shown	 that	CB2	 receptor	 agonists	 produce	
antinociceptive effects in models of nociceptive 
pain	 [37,	 38].	 Stimulation	 of	 the	 endocannabinoid	
release,	 the	 influence	 on	 cannabinoid-degrading	
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enzymes,	 activation	 of	 cannabinoid	 receptors	 by	
exogenous	 cannabinoid-like	 substances	 found	 in	 
A. h.-a.,	and	inhibition	of	release	of	chemical	mediators	
of	 inflammation	 are	 other	 possible	 mechanisms	 by	
which	aq.	ex.,	astragalin,	and	eupatilin	 from	A. h.-a. 
produce	 antinociception.	These	 possibilities remain 
only	speculative	and	await	further	testing.
The	second	phase	of	formalin	hyperalgesia	is	based	
on	 an	 inflammatory	 component	 since	 it	 has	 been	
shown	 that	 IL-1β	 and	 TNF-α	 are	 involved	 in	 this	
late	phase,	and	 that	nonselective	COX	inhibitors	are	
effective in reducing remote pain in the formalin test 
[39].	Since	aq.	ex.	of	A. h.-a.,	astragalin,	and	eupatilin	
inhibit	 phase	 2	 in	 the	 formalin	 test,	 it	 is	 likely	 that	
they	exert	their	antinociceptive	effects	by	suppressing	
the	synthesis	or	production	of	inflammatory	cytokines	
and	mediators	such	as	prostaglandins,	histamine,	and	
kinins.	This	suggestion	is	supported	by	the	observation	
that the A.	 aq.	 ex.,	 astragalin,	 and	 eupatilin caused 
dose-dependent inhibition of carrageenan-induced 
edema.
Notably,	 the	 effects	 of	 aq.ex.,	 astragalin,	 and	
eupatilin were more prominent during the second tonic 
phase	than	within	the	early	phase	of	formalin-induced	
pain.	This	observation	suggests	 that	 these	drugs	may	
be	more	effective	with	 respect	 to	 tonic	 inflammatory	
pain	when	systemically	administered.
Carrageenan-induced rat paw edema is a suitable 
test	for	evaluating	anti-inflammatory	effects	of	A. h.-a. 
aq.	 ex.,	 astragalin,	 and	 eupatilin.	 Inflammation	 is	
characterized	by	the	production	of	a	host	of	chemical	
mediators	 including	 prostaglandins,	 leukotrienes,	
histamine,	 bradykinins,	 a	 platelet	 activating	 factor,	
and	 cytokines	 (such	 as	 IL-1	 and	 TNF-a),	 by	 the	
release of chemicals from tissues and migrating 
cells,	and	also	by	hyperproduction	of	reactive	oxygen	
species	 [40,	41].	Carrageenan-induced	 inflammation	
in	 the	paw	is	a	biphasic	event	 [42].	The	 initial	phase	
observed during the first hour is attributed to release 
of	 histamine,	 serotonin,	 and	 cytokines	 (such	 as	
TNF-a),	which	leads	to	infiltration	of	neutrophils	and	
production	 of	 neutrophil-derived	 free	 radicals	 (such	
as	hydrogen	peroxide,	superoxide,	and	hydroxyl)	[43,	
44].	The	second	phase	of	edema	is	due	 to	 the	release	
of	prostaglandins,	proteases,	and	 lysosomal	enzymes	
[42,	 43].	 The	 observation	 that	 aq.	 ex.,	 astragalin,	
and eupatilin reduced in the dose-dependent manner 
carrageenan-induced paw edema suggests that these 
drugs	 may	 inhibit	 the	 synthesis	 and/or	 production	
of	 inflammatory	 mediators.	 It	 is	 noteworthy	 that	
the	 effects	 of	 aq.	 ex.,	 astragalin,	 and	 eupatilin	were	
nearly	the	same	as	that	of	indomethacin	(nonselective	
inhibitor	 of	 COX	 used	 as	 a	 reference	 drug)	 even	
though	the	doses	used	were	rather	high.
No	 signs	 of	 toxicity,	 such	 as	 diarrhea,	 motor	
impairment,	ataxia,	hyperexcitability,	or	alterations	of	
the	 respiratory	frequency	or	piloerection,	were	noted	
in	the	control	or	experimental	animals.	Also,	no	gastric	
ulcerogenic effect was observed in controls or treated 
animals.	The	LD50	for	the	aq.	ex.	of	A. h.-a.	was	found	
to	be	greater	than	2000	mg/	kg,	indicating	the	relative	
safety	of	this	remedy	(unpublished	observations).
Therefore,	 the	 results	 of	 our	 study	 directly	
demonstrated,	 for	 the	 first	 time,	 that	 aq.	 ex.	 of	 
A. h.-a.,	 astragalin,	 and	eupatilin	possess	 significant	
antinociceptive	 and	 anti-inflammatory	 properties	
exerted	 both	 centrally	 and	 peripherally,	 as	 was	
demonstrated	 in	 the	hot-plate	 test,	 formalin	 test,	and	
carrageenan-induced	 paw	 edema	 test.	 These	 effects	
seem	 to	 be	 mediated,	 but	 only	 partly,	 by	 opioid	
receptors.	Other	mechanisms,	such	as	involvement	of	
TRPA1s	or	TRPVs,	have	also	been	discussed.	
These results support the ethnomedical use of this 
plant	 and	 suggest	 that	 the	 extract	 and/or	 its	 active	
constituents might represent potential therapeutic 
options	for	the	treatment	of	pain-related	diseases.	
Acknowledgments. The authors are grateful to the 
Hashemite	University	and	Inaya	Medical	College	for	providing	
the	facilities	and	financial	support	to	conduct	the	study.
The	 experiments	were	 carried	 out	 in	 accordance	with	 the	
internationally	accepted	statements	and	current	guidelines	 for	
the	care	of	laboratory	animals	at	the	Hashemite	University.
The	 authors,	 E.	 Qnais,	 D.	 Raad,	 and	Y.	 Bseiso,	 have	 no	
conflict	of	interest.	
Е. Кнаїс1, Д. Раад1, І. Бсеізо1
АНАЛГЕТИЧНІ	ТА	ПРОТИЗАПАЛЬНІ	ЕФЕКТИ	ЕК-
СТРАКТУ	ТА		ФЛАВОНОЇДІВ	БІЛОГО	ПОЛИНУ	ТА	ЇХ	
МЕХАНІЗМИ	
1	Хашемітський	Університет,	Зарка	(Йорданія).
Р	е	з	ю	м	е
Білий	полин	(Artemisia herba-alba	–	A. h.-a.)	знаходить	ши-
роке	застосування	в	традиційній	медицині.	Його	вживають	
для	припинення	кашлю,	лікування	ран,	 	 вгамування	болю	
при	шлунково-кишкових	розладах	та	ін.	В	експериментах	in 
vivo ми	досліджували	антиноцицептивні	та	протизапальні	
ефекти	водного	екстракту	(в.	екс.)	та	двох	окремих	компо-
нентів,	отриманих	із	надземних	частин	A. h.-a.	Аналгетичні	
ефекти	в.	екс.	(10,	31.6,	100,	316	та	1000	мг/кг),	астрагаліну	
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та	еупатиліну	(обидва	в	дозах	0.316,	1,	3.16,	10,	31.6	та	100	
мг/кг)	визначались	у	тесті	«гарячої	платівки»	на	мишах	та	
формаліновому	тесті	на	щурах;	ці	ефекти	порівнювали	з	та-
кими	морфіну.	Залежні	від	дози	аналгетичні	впливи	в.	екс.,	
астрагаліну	та	 еупатиліну	яскраво	проявлялись	як	у	 тесті	
«гарячої	платівки»,	так	 і	в	перебігу	ранньої	та	пізньої	фаз	
реакції	лизання	кінцівки,	індукованої	ін’єкцією	формаліну.	
Ці	 ефекти	 усувались,	 проте	 лише	 частково,	 антагоністом	
опіоїдних	рецепторів	налоксоном	(5	мг/кг).	Аналогічні	дози	
в.	екс.,	астрагаліну	та	еупатиліну	забезпечували	дозозалеж-
не	пригнічення	індукованого	карагенаном	набряку	кінцівки	
у	щурів.	Таким	чином,	ми	продемонстрували,	що	для	A. h.-
a.	 характерні	 істотні	 антиноцицептивна	 та	протизапальна	
властивості.	Наші	дані	підтверджують	обгрунтованість	за-
стосування	цієї	рослини	як	лікувального	засобу	в	традицій-
ній	медицині.	Згадані	властивості	A. h.-a.	в	істотній	мірі	за-
лежать	від	наявності	в	її	складі	астрагаліну	та	еупатиліну.	
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